NASH was not done for shareholders. Right now the market has shown they couldn't care less about another indication. So who was this study done for? Ask yourself that question. We are not privy to what management knows. But we have seen BPs make public statements about NASH.

The market is waiting on financing, and/or partnership deal, and/or BLA. Once one of those happens, the market must then assign value to all these indications it has ignored along the way.

The problem with the stock it has many non-otc investors that are not familiar with otc stocks. Most otc only dream of the situation cydy is in right now. I've seen other otc stocks run on deals less than a million dollars, here we are talking in possible billions. I'm seeing more big otc names on ihub being interested in the story here.